Imatinib-induced ulcerative colitis
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Oncology Pharmacy Practice"
DOI: 10.1177/10781552241255290
Abstract: Introduction Imatinib, a tyrosine kinase inhibitor, is the first-line therapy for patients with KIT mutation in gastrointestinal stromal tumor (GIST). Nausea, vomiting, diarrhea, dyspepsia and abdominal pain are common gastrointestinal adverse reactions of imatinib, but… read more here.
Keywords: imatinib; induced ulcerative; ulcerative colitis; induced imatinib ... See more keywords